Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes.
Servetto A, Di Maio M, Salomone F, Napolitano F, Paratore C, Di Costanzo F, Viscardi G, Santaniello A, Formisano L, Bianco R.
Servetto A, et al.
BMC Med. 2023 Jul 3;21(1):234. doi: 10.1186/s12916-023-02953-0.
BMC Med. 2023.
PMID: 37400832
Free PMC article.
Clinical Trial.
For each RCT, we assessed whether global QoL was "superior," "inferior," or with "non-statistically significant difference" in the experimental arm compared to the control arm. RESULTS: Experimental treatments led to superior QoL in 30 (37.0%) RCTs and inferior QoL …
For each RCT, we assessed whether global QoL was "superior," "inferior," or with "non-statistically significant difference" in the experimen …